Changchun GeneScience Pharmaceutical Co., Ltd.: Dwarfism, Pituitary trials
The registry lists 10 Dwarfism, Pituitary studies with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 1 1Phase 2 3Phase 3 1Phase 4 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)RecruitingNCT07016802Phase 1
- A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)TerminatedNCT07259564Phase 2
- Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone DeficiencyStatus unknownNCT03249480Phase 4
- A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHDStatus unknownNCT03104010Phase 2
- Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone DeficiencyStatus unknownNCT02976675Phase 4
- Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone DeficiencyStatus unknownNCT02908958Phase 4
- Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I)Status unknownNCT02380235Phase 4
- Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency ChildrenStatus unknownNCT02314676Phase 4
- Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency ChildrenCompletedNCT01495468Phase 3
- Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency ChildrenCompletedNCT01342146Phase 2